7383 results about "Diabetes mellitus" patented technology

An integrated system for the monitoring and treating diabetes is provided, including an integrated receiver / hand-held medicament injection pen, including electronics, for use with a continuous glucose sensor. In some embodiments, the receiver is configured to receive continuous glucose sensor data, to calculate a medicament therapy (e.g., via the integrated system electronics) and to automatically set a bolus dose of the integrated hand-held medicament injection pen, whereby the user can manually inject the bolus dose of medicament into the host. In some embodiments, the integrated receiver and hand-held medicament injection pen are integrally formed, while in other embodiments they are detachably connected and communicated via mutually engaging electrical contacts and / or via wireless communication.

An integrated system for the monitoring and treating diabetes is provided, including an integrated receiver / hand-held medicament injection pen, including electronics, for use with a continuous glucose sensor. In some embodiments, the receiver is configured to receive continuous glucose sensor data, to calculate a medicament therapy (e.g., via the integrated system electronics) and to automatically set a bolus dose of the integrated hand-held medicament injection pen, whereby the user can manually inject the bolus dose of medicament into the host. In some embodiments, the integrated receiver and hand-held medicament injection pen are integrally formed, while in other embodiments they are detachably connected and communicated via mutually engaging electrical contacts and / or via wireless communication.

Method and system for providing diabetes management is provided.

An automated healthcare communication system that facilitates communications between healthcare providers and patients and provides timely data to providers to help patients self manage their diabetes. Messages are presented to patients at pre-selected times to help them learn about the disease and develop appropriate behaviors that improve their health and to prompt them for data or for answers to specific questions or surveys. The system applies advanced speech recognition technology to make the system easy for patients to use and understand via a telephone network. Data collected from the patient is presented in real-time to healthcare providers so the patients' progress can be monitored and treatment plans adjusted accordingly.

This invention describes novel pyrazole compounds of formula IIIa: wherein R1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx, Ry, R2; and R2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

A system, method and apparatus for real time measurement and monitoring of various personal health parameters including controlled delivery of drugs / medications by intelligent pump appliances, intelligent inhalation appliances and intelligent skin patch appliances used in a standalone manner or in a wired or wireless networked configuration, in conjunction with various peripheral devices, other intelligent appliances, servers, RF ID Tags and stationary / mobile devices. The intelligent appliances relate to the measurement, monitoring and delivery of insulin / other drugs for the treatment of diabetes and other diseases. The method also additionally includes the application of intelligent appliances for pain management including visualization of organs and body locations exhibiting pain.

Method and apparatus for monitoring the sleep state condition of an individual by using an external probe applied to a peripheral body location, such as the individual's finger or toe, for detecting changes in the peripheral vascular bed volume of the individual. A predetermined pressure field is applied to the distal end of the peripheral body location, including its distal-most extremity, to prevent the occurrence of venous pooling within and distal to the peripheral body location. The probe produces an output corresponding to changes in the peripheral arterial bed volume at the peripheral body location, which output provides an indication of the sleep state condition of the individual. Such information is useful in diagnosing and / or in treating, a number of sleep disorders as well as other conditions, such as impotence, diabetes, and various disorders in children.

The invention is directed to methods and systems of hyperspectral and multispectral imaging of medical tissues. In particular, the invention is directed to new devices, tools and processes for the detection and evaluation of diseases and disorders such as, but not limited to diabetes and peripheral vascular disease, that incorporate hyperspectral or multispectral imaging.

Methods, systems and devices for detecting an analyte sample, determining an analyte concentration associated with the detected analyte sample, storing the determined analyte concentration and a time associated with the determined analyte concentration, retrieving two or more stored analyte concentrations, and determining an adjusted dose level based at least in part on a current dose level and data associated with the two or more retrieved analyte concentrations are provided. For example, adjustments to dosage levels of long-acting insulin may be provided to assist in the management of diabetes and related conditions.

Patients with certain chronic diseases such as diabetes require medical treatment according to a set time-related treatment plan. Such a treatment plan must be adapted accordingly in the case of long-haul journeys to countries with a time difference. A method for this has the steps of recording an regular treatment plan for administering the medicine, recording the point of departure and destination as well as the time of travel of the long-haul journey, determining the time zone difference between the point of departure and the destination and producing an adapted travel treatment plan based on the regular treatment plan depending on the time zone difference and the time of travel. The invention enables a patient to achieve a structured adaptation of his individual treatment plan to the time difference in the destination country of the journey in a convenient manner.

The present invention provides devices and methods for attachment of an endolumenal gastrointestinal device, such as an artificial stoma device, a gastrointestinal bypass sleeve or other therapeutic or diagnostic device, within a patient's digestive tract. In one application of the invention, an endolumenal bypass sleeve is removeably attached in the vicinity of the gastroesophageal junction to treat obesity and / or its comorbidities, such as diabetes. The bypass sleeve may be at least partially deployed by eversion.

The invention relates to: A portable medication delivery device (1) comprising a medication cartridge (11) having an outlet (111) and a movable piston (112), and a housing (12) for holding said cartridge, and a flexible piston rod (13) being operable to engage and displace said piston along an axis (113) of said cartridge, and guiding means (14) for bending said piston rod away from said axis, and actuating means (15), and driving means (16, 17) for transferring movement from said actuating means to said piston rod, said driving means including a driving wheel (17) for displacing the piston rod (13), said flexible piston rod comprising regularly spaced first members (330; 331; 332) adapted to mechanically cooperate with corresponding second members (171) on said driving wheel. The object of the present invention is to provide a medication delivery system that combines compactness with an improved accuracy. The problem is solved in that said flexible piston rod (13) exhibits a linear or approximately linear path between said driving wheel (17) and said piston (112). This has the advantage of yielding a compact, low-weight device with an improved dose accuracy. The invention may e.g. be used in injection or infusion devices for a person's self-treatment of a disease such as diabetes.

Embodiments of the invention provide amperometric analyte sensors having multiple related structural elements (e.g. sensor arrays comprising a working, counter and reference electrode) and algorithms designed for use with such sensors. While embodiments of the innovation can be used in a variety of contexts, typical embodiments of the invention include glucose sensors used in the management of diabetes.

Methods for treating metabolic disorders, including diabetes and obesity, using TNFalpha inhibitors are described.

A disease management system, methods, and devices are shown and described. In one embodiment, the system includes an infusion pump and a remote controller with the ability to be paired to each other. A method to verify a wireless connection between an infusion pump and a remote controller is shown and described herein. In a further embodiment, a method to verify a wireless connection between an infusion pump and a remote controller is provided. In addition, a method of operating a diabetes management system is provided in which the system includes an infusion pump and at least a remote controller.

A disease management system, methods, and devices are shown and described. In one embodiment, the system includes an infusion pump and a remote controller with the ability to be paired to each other. A method to verify a wireless connection between an infusion pump and a remote controller is shown and described herein. In a further embodiment, a method to verify a wireless connection between an infusion pump and a remote controller is provided. In addition, a method of operating a diabetes management system is provided in which the system includes an infusion pump and at least a remote controller.

Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.

This invention comprises administering to a human or animal in need of treatment an effective amount of an antioxidant lipoic acid derivative and / or pharmaceutically acceptable salts and solvates thereof for the treatment or prevention of pathological (inflammatory, proliferative and degenerative diseases, e.g. diabetes mellitus, atherosclerosis, Alzheimer's disease and chronic viral diseases) and non-pathological (e.g. skin aging and wrinkle formation) conditions caused by oxidative damage. Methods of synthesizing novel antioxidant lipoic acid derivatives and their use in preventing or treating diseases or conditions caused by oxidative stress and other free radical mediated conditions are described. Another aspect of this invention is the use of these antioxidant compositions for the protection of skin from damage caused by ultraviolet radiation and dessication, and to provide improved skin feel by desquamating, cleansing and clarifying the skin. The compositions described in this invention increase cellular viability of epidermal cells, promote cytoprotection, and decrease the production of inflammatory mediators such as inflammatory cytokines in these cells. The antioxidant compositions are incorporated into sunscreen products, soap, moisturizing lotions, skin toners, and other skin care products.

An apparatus comprising a pump configured to deliver insulin, an input configured to receive information related to managing diabetes of a user, a user interface, and a controller communicatively coupled to the pump, the input, and the user interface. The controller includes an insulin timing module configured to initiate delivery of insulin in a time relation to when a meal is to be consumed by the user and to adjust delivery of the insulin according to the received information. Other devices, systems, and methods are disclosed.

A composition is disclosed comprising glucagon-like peptide 1 (GLP-1) particles in combination with diketopiperazine (DKP) that is stable both in vitro and in vivo. The composition has utility as a pharmaceutical formulation for treating diseases such as diabetes, cancers, and obesity but is not limited to such diseases or conditions. In particularly, the composition has utility as a pharmaceutical formulation for pulmonary delivery.

Disclosed are methods for the use of therapeutic polypeptide-encoding polynucleotides in the creation of transformed host cells and transgenic animals. In particular, the use of recombinant adeno-associated viral (rAAV) vector compositions that specifically target mammalian cells, such as pancreatic islets cells, that express low-density lipoprotein receptors on their cell surface. The disclosed vectors comprise one or more polynucleotide sequences that express one or more mammalian polypeptides having therapeutic efficacy in the amelioration, treatment and / or prevention of AAT- or cytokine polypeptide deficiencies, such as for example in diabetes and related diseases, as well as a variety of autoimmune disorders including, for example, lupus and rheumatoid arthritis.

This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

The present invention teaches a method and apparatus for physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity, depression, epilepsy, and diabetes. This includes chronically implanted neural and neuromuscular modulators, used to modulate the afferent neurons of the sympathetic nervous system to induce satiety. Furthermore, this includes neuromuscular stimulation of the stomach to effect baseline and intermittent smooth muscle contraction to increase gastric intraluminal pressure, which induces satiety, and stimulate sympathetic afferent fibers, including those in the sympathetic trunk, splanchnic nerves, and greater curvature of the stomach, to augment the perception of satiety.

A disease management system, methods, and devices are shown and described. In one embodiment, the system includes an infusion pump and a remote controller with the ability to be paired to each other. A method to verify a wireless connection between an infusion pump and a remote controller is shown and described herein. In a further embodiment, a method to verify a wireless connection between an infusion pump and a remote controller is provided. In addition, a method of operating a diabetes management system is provided in which the system includes an infusion pump and at least a remote controller.

This invention provides compositions comprising a byetta, fish oil, and a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral or rectal administration of a byetta.